Form 4: Stoke Therapeutics Insider Sells Shares Under 10b5-1 Plan

Stoke Therapeutics General Counsel & Corp Sec, Jonathan Allan, reported a sale of 1,457 common shares on June 16, 2026, executed under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Jonathan Allan, General Counsel & Corporate Secretary of Stoke Therapeutics, Inc., sold 1,457 shares of common stock on June 16, 2026.
• The transaction was conducted under a Rule 10b5-1 trading plan adopted on November 10, 2025.
• The sale price was $29.95 per share.
• Following this transaction, Allan beneficially owns 18,086 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing neutrally as it represents a routine insider transaction executed under a pre-defined plan, providing transparency without immediate implications for company valuation.

Negatives

• Insider selling can sometimes be perceived negatively by the market, although this sale was conducted under a pre-established plan.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding future company performance.

Industry Context

StockSavvy.ai notes that Form 4 filings, particularly those executed under Rule 10b5-1 plans, are standard disclosures for insider transactions. While not indicative of company performance, they provide transparency regarding executive stock dealings.

Stakeholder Impact

• Shareholders: The sale is executed under a pre-arranged plan, mitigating concerns of opportunistic insider trading. However, any insider selling can be a point of observation for investors.

Key Dates

Keywords

Form 4, Insider Trading, Rule 10b5-1, Stoke Therapeutics, Stock Sale, Beneficial Ownership, SEC Filing